Top

Published in:

01-04-2014 | Original Article

Netrin-1, a urinary proximal tubular injury marker, is elevated early in the time course of human diabetes

Authors: Calpurnia Jayakumar, Ferdau L. Nauta, Stephan J. L. Bakker, Henk Bilo, Ron T. Gansevoort, Maribeth H. Johnson, Ganesan Ramesh

Published in: Journal of Nephrology | Issue 2/2014

Abstract

Background

Netrin-1 was recently identified as an early diagnostic biomarker of chronic kidney disease (CKD) in an experimental animal model. However, its usefulness for early diagnosis of CKD in humans is unknown. The current study evaluated whether netrin-1 is increased in urine from human diabetic patients.

Methods

Spot urine samples from healthy volunteers, diabetes without microalbuminuria, diabetes with microalbuminuria and diabetes with macroalbuminuria were collected after receiving consent. Netrin-1 in urine was quantified by enzyme-linked immunosorbent assay and the data analyzed to determine whether urinary netrin-1 significantly correlates with disease progression.

Results

Urinary netrin-1 levels were significantly increased in normoalbuminuric diabetic patients compared to healthy controls, and still further elevated in patients with microalbuminuria and overt nephropathy. Urinary netrin-1 was significantly associated with albuminuria and estimated glomerular filtration rate, independently of age and sex.

Conclusion

Netrin-1 is detectable in urine from diabetic patients and may serve as a useful early diagnostic biomarker predicting the development of CKD in diabetes.

Available only for authorised users

Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25:496–501PubMedCrossRef

Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984) Structural-functional relationships in diabetic nephropathy. J Clin Invest 74:1143–1155PubMedCentralPubMedCrossRef

Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M (2005) The early natural history of nephropathy in type 1 diabetes. Diabetes 54:2164–2171PubMedCrossRef

Gekle M (1998) Renal proximal tubular albumin reabsorption: daily prevention of albuminuria. News Physiol Sci 13:5–11PubMed

Amsellem S, Gburek J, Hamard G, Nielsen R, Willnow TE, Devuyst O, Nexo E, Verroust PJ, Christensen EI, Kozyraki R (2010) Cubilin is essential for albumin reabsorption in the renal proximal tubule. J Am Soc Nephrol 21:1859–1867PubMedCentralPubMedCrossRef

Russo LM, Sandoval RM, Campos SB, Molitoris BA, Comper WD, Brown D (2009) Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 20:489–494PubMedCentralPubMedCrossRef

Nauta FL, Boertien WE, Bakker SJL, van Goor H, van Oeveren W, de Jong PE, Bilo H, Gansevoort RT (2011) Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 34:975–981PubMedCentralPubMedCrossRef

Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH, Krolewski AS, Bonventre JV (2011) Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-[beta]-d-glucosaminidase. Kidney Int 79:464–470PubMedCentralPubMedCrossRef

Reeves WB, Kwon O, Ramesh G (2008) Netrin-1 and kidney injury. II. Netrin-1 is an early biomarker of acute kidney injury. Am J Physiol Renal Physiol 294:F731–F738PubMedCrossRef

10.

Ramesh G, Krawczeski CD, Woo JG, Wang Y, Devarajan P (2010) Urinary netrin-1 is an early predictive biomarker of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 5:395–401PubMedCentralPubMedCrossRef

11.

Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, Zeeuw DD, Hostetter TH, Lameire N, Eknoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 67:2089–2100PubMedCrossRef

12.

White JJ, Mohamed R, Jayakumar C, Ramesh G (2013) Tubular injury marker netrin-1 is elevated early in experimental diabetes. J Nephrol 26:1055–1064PubMedCrossRef

13.

Fu WJ, Xiong SL, Fang YG, Wen S, Chen ML, Deng RT, Zheng L, Wang SB, Pen LF, Wang Q (2012) Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 41:82–88

14.

Brito PL, Fioretto P, Drummond K, Kim Y, Steffes MW, Basgen JM, Sisson-Ross S, Mauer M (1998) Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 53:754–761PubMedCrossRef

15.

Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R (1996) Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39:1569–1576PubMedCrossRef

16.

Yu Y, Jin H, Holder D, Ozer JS, Villarreal S, Shughrue P, Shi S, Figueroa DJ, Clouse H, Su M, Muniappa N, Troth SP, Bailey W, Seng J, Aslamkhan AG, Thudium D, Sistare FD, Gerhold DL (2010) Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28:470–477PubMedCrossRef

17.

Ovunc B, Otto EA, Vega-Warner V, Saisawat P, Ashraf S, Ramaswami G, Fathy HM, Schoeb D, Chernin G, Lyons RH, Yilmaz E, Hildebrandt F (2011) Exome sequencing reveals cubilin mutation as a single-gene cause of proteinuria. J Am Soc Nephrol 22:1815–1820PubMedCentralPubMedCrossRef

18.

Wilson BD, Ii M, Park KW, Suli A, Sorensen LK, Larrieu-Lahargue F, Urness LD, Suh W, Asai J, Kock GA, Thorne T, Silver M, Thomas KR, Chien CB, Losordo DW, Li DY (2006) Netrins promote developmental and therapeutic angiogenesis. Science 313:640–644PubMedCentralPubMedCrossRef

19.

Liu J, Xia X, Xiong S, Le Y, Xu H (2011) Intravitreous high expression level of netrin-1 in patients with proliferative diabetic retinopathy. Yan Ke Xue Bao 26:35–42

20.

Tian XF, Xia XB, Xiong SQ, Jiang J, Liu D, Liu JL (2011) Netrin-1 overexpression in oxygen-induced retinopathy correlates with breakdown of the blood-retina barrier and retinal neovascularization. Ophthalmologica 226:37–44PubMedCrossRef

21.

Mohamed R, Jayakumar C, Ranganathan PV, Ganapathy V, Ramesh G (2012) Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppresses inflammation and albuminuria through suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice. Am J Pathol 181:1991–2002PubMedCentralPubMedCrossRef

22.

Rajasundari A, Pays L, Mehlen P, Ramesh G (2011) Netrin-1 overexpression in kidney proximal tubular epithelium ameliorates cisplatin nephrotoxicity. Lab Invest 91:1717–1726PubMedCentralPubMedCrossRef

23.

Wang W, Reeves WB, Pays L, Mehlen P, Ramesh G (2009) Netrin-1 overexpression protects kidney from ischemia reperfusion injury by suppressing apoptosis. Am J Pathol 175:1010–1018PubMedCentralPubMedCrossRef

24.

Tadagavadi RK, Wang W, Ramesh G (2010) Netrin-1 regulates Th1/Th2/Th17 cytokine production and inflammation through UNC5B receptor and protects kidney against ischemia-reperfusion injury. J Immunol 185:3750–3758PubMedCrossRef

25.

Jayakumar C, Mohamed R, Ranganathan PV, Ramesh G (2011) Intracellular kinases mediate increased translation and secretion of netrin-1 from renal tubular epithelial cells. PLoS One 6:e26776PubMedCentralPubMedCrossRef

Title: Netrin-1, a urinary proximal tubular injury marker, is elevated early in the time course of human diabetes
Authors: Calpurnia Jayakumar
Ferdau L. Nauta
Stephan J. L. Bakker
Henk Bilo
Ron T. Gansevoort
Maribeth H. Johnson
Ganesan Ramesh
Publication date: 01-04-2014
Publisher: Springer International Publishing
Published in: Journal of Nephrology / Issue 2/2014
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-014-0055-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2014

Nephrolithiasis by Corynebacterium urealyticum infection: literature review and case report

Geriatric nutritional risk index is a strong predictor of mortality in hemodialysis patients: data from the Riscavid cohort

Amyloid beta 1–42 and tau in the cerebrospinal fluid of renal failure patients for the diagnosis of Alzheimer′s disease

Membranoproliferative glomerulonephritis associated with autoimmune diseases

Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial

Pentraxin 3 as a novel bio-marker of inflammation and endothelial dysfunction in autosomal dominant polycystic kidney disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials